Top Ten Stocks in Focus on Monday, 22 August 2016
The Indian market is expected to open flat on Monday tracking mixed trend seen in other Asian markets.
Here is a list of Top Ten Stocks that are likely to be in focus today
Banking stocks will be in focus after the Appointments Committee of the Cabinet (ACC) on late Saturday announced the appointment of Reserve Bank of India Deputy Governor Urijit Patel as successor to Governor Raghuram Rajan.
United Bank of India: The government will infuse Rs 608 crore in state run United Bank of India soon subscribing to the bank’s shares at Rs 22.73 including Rs 12.73 premium per share.
Cairn India: Vedanta Ltd’s chief executive said the diversified Indian miner received “constructive feedback” from minority shareholders in Cairn India LtdBSE -1.80 % to a sweetened buyout offer, and was hopeful it can clinch the long-delayed deal.
M&M: Mahindra & Mahindra (M&M) is said to have begun working on what is being pegged as the most affordable electric SUV in the world through its Mahindra Electric unit, formerly known as Mahindra Reva.
Oberoi Realty: The company reported 33.1 per cent YoY jump in the net profit to Rs 109 crore for the quarter ended June 30 compared with 81.9 crore reported in the year-ago period.
Corporation Bank: Corporation Bank seeks members’ nod to issue equity shares on preferential basis to the government of India to the tune of Rs 508 crore.
DB Corp : ET NOW learns that Tata Power is in talks with Bhopal headquartered leading print media company DB Corp for a potential buyout of the promoter owned power generation arm Diligent Power, according to four individuals familiar with ongoing negotiations.
Ujjivan Financial Services: The company submitted an application to RBI for a small finance bank licence for its subsidiary.
Cosmo Films: Cosmo Films’ wholly owned subsidiary – CF Global Holding Mauritius, has filed a petition for liquidation of its wholly owned entity namely Cosmo Films (Netherlands) Cooperatief U.A, said a media report.
Ranbaxy Laboratories: Sun PharmaBSE -1.09 % seems to have completed the last leg of its massive manpower restructuring post its $3.2-billion acquisition of Ranbaxy Laboratories, with four senior executives exiting the company over the last two months.
FOR FREE TRAIL : REGISTER NOW